QQ客服 官方微博 反馈留言

	Management of anlotinib-related adverse events in patients with advanced non-small cell lung cancer: Experiences in ALTER-0303
	Si, Xiaoyan; Zhang, Li; Wang, Hanping; Zhang, Xiaotong; Wang, Mengzhao; Han, Baohui; Li, Kai; Wang, Qiming; Shi, Jianhua; Wang, Zheh 更多
刊名	THORACIC CANCER
	2019
卷号	10期号:3页码:551-556
关键词	Adverse event anlotinib multi-target tyrosine kinase inhibitor non-small cell lung cancer
DOI	10.1111/1759-7714.12977
URL标识	查看原文
公开日期	[db:dc_date_available]
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/4537958
专题	山东大学
作者单位	1.Peking Union Med Coll Hosp, Resp Med, Beijing, Peoples R China. 2.[Han, Baoh
推荐引用方式 GB/T 7714	Si, Xiaoyan,Zhang, Li,Wang, Hanping,et al. Management of anlotinib-related adverse events in patients with advanced non-small cell lung cancer: Experiences in ALTER-0303[J]. THORACIC CANCER,2019,10(3):551-556.
APA	Si, Xiaoyan.,Zhang, Li.,Wang, Hanping.,Zhang, Xiaotong.,Wang, Mengzhao.,...&Wang, Zheh 更多.(2019).Management of anlotinib-related adverse events in patients with advanced non-small cell lung cancer: Experiences in ALTER-0303.THORACIC CANCER,10(3),551-556.
MLA	Si, Xiaoyan,et al."Management of anlotinib-related adverse events in patients with advanced non-small cell lung cancer: Experiences in ALTER-0303".THORACIC CANCER 10.3(2019):551-556.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。